WO2007084661B1 - Therapy-enhancing glucan - Google Patents
Therapy-enhancing glucanInfo
- Publication number
- WO2007084661B1 WO2007084661B1 PCT/US2007/001427 US2007001427W WO2007084661B1 WO 2007084661 B1 WO2007084661 B1 WO 2007084661B1 US 2007001427 W US2007001427 W US 2007001427W WO 2007084661 B1 WO2007084661 B1 WO 2007084661B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glucan
- subject
- antibodies
- amended
- cancer
- Prior art date
Links
- 229920001503 Glucan Polymers 0.000 title claims abstract 9
- 239000000203 mixture Substances 0.000 claims abstract 12
- 229940022399 cancer vaccine Drugs 0.000 claims abstract 5
- 238000009566 cancer vaccine Methods 0.000 claims abstract 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 201000011510 cancer Diseases 0.000 claims abstract 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract 3
- 230000003213 activating effect Effects 0.000 claims 4
- 230000001093 anti-cancer Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000005975 antitumor immune response Effects 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 150000002270 gangliosides Chemical class 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 230000037452 priming Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 abstract 1
- 229920002498 Beta-glucan Polymers 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a yeast beta-glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal. The above therapeutic composition may further comprise antitumor antibodies or cancer vaccine composition, wherein the antitumor activitiesof the antitumor antibodies or the cancer vaccine composition are enhanced by the yeast glucan.
Claims
AMENDED CLAIMS received by the International Bureau on 26 November 2007 (26.11.2007)
1-17 . ( canceled)
18. (amended) A use of an effective amount of yeast glucan for preparing an orally administered anti-cancer pharmaceutical composition, wherein the glucan has an average molecular weight of about 16,000 to about 17,000 daltons aud a range from about 6,000 to about 30,000 daltons, .
19. The use of claim 18, wherein the anti-cancer pharmaceutical composition further comprises a cancer vaccine composition intended to induce antitumor immune responses in a subject .
20. The use of claim 18, wherein the anti-cancer pharmaceutical composition further comprises antibodies that bind to cancer cells in a subject.
21. The use of claim 20, wherein the antibodies are capable of activating complement or activating antibody dependent σell- mediated cytotoxicity.
22. The use of claim 20 or 21, wherein the antibody is monoclonal antibody.
23. (amended) The use of claim 20, wherein the antibody recognizes an antigen selected from the group consisting of CD20, CD22, HER-2/neu, CD25, epidermal growth factor receptor, and ganglioside.
24. (amended) The use of claim 20, wherein the antibodies is administered to a subject at the same or different time as the administration of the glucan.
25. (amended) The use of claim 20, wherein the antibody binds to cancer cells in a subject having neuroblastoma.
26. The use of claim 19, wherein the cancer vaccine composition is administered to a subject at the same or different time as the administration of the glucan.
27. (amended) The use of claim 18, wherein the glucan is capable of priming or inducing secretion of cytokines, chemokines or growth factors by leukocytes.
23. (new) A orally administered composition comprising (i) soluble yeaat glucan, and (ii) a cancer vaccine composition intended to induce antitumor immune responses in a subject, or antibodies that bind to cancer cells in a subject.
29. (new) The use of claim 28, wherein the antibodies are capable of activating complement or activating antibody dependent cell-mediated cytotoxicity.
30. (new) Tϊie composition of claim 28, wherein the antibodies recognizes 'an antigen selected from the group consisting of CD20, CD22, HER-2/neu, CD25, epidermal growth factor receptor, and ganglioside.
31. (new) The composition of claim 28, wherein the glucan is capable of priming or inducing secretion of cytokines, chemokines or growth factors by leukocytes.
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07718218A EP1984004A4 (en) | 2006-01-17 | 2007-01-17 | Therapy-enhancing glucan |
| US12/161,285 US8323644B2 (en) | 2006-01-17 | 2007-01-17 | Therapy-enhancing glucan |
| PCT/US2007/001427 WO2007084661A2 (en) | 2006-01-17 | 2007-01-17 | Therapy-enhancing glucan |
| CA002637205A CA2637205A1 (en) | 2006-01-17 | 2007-01-17 | Therapy-enhancing glucan |
| JP2008551413A JP2009528267A (en) | 2006-01-17 | 2007-01-17 | Glucan to enhance treatment |
| AU2008207369A AU2008207369B2 (en) | 2006-01-17 | 2008-08-18 | Immune response enhancing glucans |
| US12/212,352 US20090053221A1 (en) | 2006-01-17 | 2008-09-17 | Immune response enhancing glucan |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/334,763 | 2006-01-17 | ||
| US11/334,763 US7906492B2 (en) | 2001-01-16 | 2006-01-17 | Therapy-enhancing glucan |
| PCT/US2007/001427 WO2007084661A2 (en) | 2006-01-17 | 2007-01-17 | Therapy-enhancing glucan |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/334,763 Continuation-In-Part US7906492B2 (en) | 2001-01-16 | 2006-01-17 | Therapy-enhancing glucan |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008207369A Division AU2008207369B2 (en) | 2006-01-17 | 2008-08-18 | Immune response enhancing glucans |
| US12/212,352 Continuation-In-Part US20090053221A1 (en) | 2006-01-17 | 2008-09-17 | Immune response enhancing glucan |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2007084661A2 WO2007084661A2 (en) | 2007-07-26 |
| WO2007084661A3 WO2007084661A3 (en) | 2007-11-08 |
| WO2007084661B1 true WO2007084661B1 (en) | 2008-01-10 |
Family
ID=40382391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2007/001427 WO2007084661A2 (en) | 2006-01-17 | 2007-01-17 | Therapy-enhancing glucan |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1984004A4 (en) |
| JP (1) | JP2009528267A (en) |
| AU (1) | AU2008207369B2 (en) |
| WO (1) | WO2007084661A2 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507724B2 (en) | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US7906492B2 (en) | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| JP5153188B2 (en) * | 2007-03-30 | 2013-02-27 | 小林製薬株式会社 | Th1 / Th2 balance improver |
| AU2008322737A1 (en) * | 2007-11-13 | 2009-05-22 | Biotec Pharmacon Asa | Methods of treating or preventing inflammatory diseases of the intestinal tract |
| WO2012014978A1 (en) * | 2010-07-29 | 2012-02-02 | 国立大学法人北海道大学 | Immune adjuvant |
| JP5990752B2 (en) * | 2011-01-31 | 2016-09-14 | オリンパス株式会社 | Antibody therapy effect enhancer |
| EP3373006A1 (en) | 2012-04-30 | 2018-09-12 | Biothera, Inc. | Beta-glucan immunotherapeutic methods |
| EP2832360A1 (en) | 2013-07-30 | 2015-02-04 | Fresenius Kabi Deutschland GmbH | Polysaccharide for use in preventing metastasis formation and/or relapse |
| ES2877099T3 (en) * | 2014-07-10 | 2021-11-16 | Hibercell Inc | Beta-glucan in combination with anticancer agents that affect the tumor microenvironment |
| US11815435B2 (en) | 2017-02-24 | 2023-11-14 | Hibercell, Inc. | Beta glucan immunopharmacodynamics |
| BR112020018761A2 (en) * | 2018-03-13 | 2020-12-29 | Hibercell, Inc. | COMBINED IMMUNOTHERAPY WITH BETA-GLUCAN AND CD40 AGONIST |
| CA3097980A1 (en) * | 2018-04-24 | 2019-10-31 | Memorial Sloan Kettering Cancer Center | Methods of enhancing immunogenicity of poorly immunogenic antigen-specific vaccines using oral yeast beta-glucans |
| US20210290708A1 (en) * | 2018-09-21 | 2021-09-23 | Nantcell, Inc. | Methods and compositions for modulating myeloid-derived suppressor cells |
| JP7048102B2 (en) | 2019-05-23 | 2022-04-05 | 国立研究開発法人医薬基盤・健康・栄養研究所 | Application of nucleic acid polysaccharide complex with immunostimulatory activity as an antitumor drug |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340080C (en) * | 1985-03-11 | 1998-10-13 | Dorothee Herlyn | Human tumor therapy |
| EP0490995A1 (en) * | 1989-09-08 | 1992-06-24 | Alpha Beta Technology | Method for producing soluble glucans |
| US5622939A (en) * | 1992-08-21 | 1997-04-22 | Alpha-Beta Technology, Inc. | Glucan preparation |
| US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| US5696079A (en) * | 1993-05-19 | 1997-12-09 | The United States Of America As Represented By The Department Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
| EP0640348A1 (en) * | 1993-07-26 | 1995-03-01 | Akzo Nobel N.V. | Oil-based and water-based adjuvant mixture |
| NO300692B1 (en) * | 1994-04-29 | 1997-07-07 | Biotec Mackzymal As | Solubilized branched β-1,3-glucan and its use, as well as the use of unsolubilized branched β-1,3-glucan |
| JP2000516911A (en) * | 1996-03-28 | 2000-12-19 | ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ | Opsonin-enhanced cells and methods of modulating the immune response to antigens |
| JP2004507446A (en) * | 2000-02-04 | 2004-03-11 | トーマス・ジェファーソン・ユニバーシティ | Immunotherapy of low-dose haptenized tumor cells and tumor cell extracts |
| EP1357919B1 (en) * | 2001-01-16 | 2017-04-05 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US7507724B2 (en) * | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| GB0211118D0 (en) * | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
| AU2003295326A1 (en) * | 2002-09-04 | 2004-04-23 | Cancer therapy using beta glucan and antibodies | |
| US20090214562A1 (en) * | 2005-05-03 | 2009-08-27 | Karel Steven J | Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection |
-
2007
- 2007-01-17 EP EP07718218A patent/EP1984004A4/en not_active Withdrawn
- 2007-01-17 JP JP2008551413A patent/JP2009528267A/en active Pending
- 2007-01-17 WO PCT/US2007/001427 patent/WO2007084661A2/en active Application Filing
-
2008
- 2008-08-18 AU AU2008207369A patent/AU2008207369B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1984004A2 (en) | 2008-10-29 |
| JP2009528267A (en) | 2009-08-06 |
| AU2008207369B2 (en) | 2009-12-17 |
| AU2008207369A1 (en) | 2008-09-11 |
| WO2007084661A3 (en) | 2007-11-08 |
| EP1984004A4 (en) | 2010-03-03 |
| WO2007084661A2 (en) | 2007-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007084661B1 (en) | Therapy-enhancing glucan | |
| US10786552B2 (en) | Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody | |
| Jin et al. | β-glucans as potential immunoadjuvants: A review on the adjuvanticity, structure-activity relationship and receptor recognition properties | |
| Zhang et al. | Optimizing tumor microenvironment for cancer immunotherapy: β-glucan-based nanoparticles | |
| JP6622238B2 (en) | Methods for inhibiting protein fucosylation in vivo using fucose analogs | |
| JP4903041B2 (en) | Glucan to enhance treatment | |
| Kayser et al. | Natural products and synthetic compounds as immunomodulators | |
| US8323644B2 (en) | Therapy-enhancing glucan | |
| EP2703011A3 (en) | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
| US20180256738A1 (en) | Beta-glucan compounds, compositions, and methods | |
| Baran et al. | Oral beta-glucan adjuvant therapy converts nonprotective Th2 response to protective Th1 cell-mediated immune response in mammary tumor-bearing mice. | |
| WO2006119395A2 (en) | Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection | |
| WO2010132622A2 (en) | Anticd20-cpg conjugates and methods of treating b cell malignancies | |
| Rawding et al. | Dendrimers for cancer immunotherapy: Avidity‐based drug delivery vehicles for effective anti‐tumor immune response | |
| US20090053221A1 (en) | Immune response enhancing glucan | |
| CN116617386B (en) | Application of tripterine or medicinal derivative thereof in preparation of vaccine adjuvant | |
| AU2002358246B2 (en) | Combination therapy for treating disease | |
| CA2637205A1 (en) | Therapy-enhancing glucan | |
| JP2023073529A (en) | complex | |
| AU2002358246A1 (en) | Combination therapy for treating disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2637205 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008551413 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12161285 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1729/MUMNP/2008 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007718218 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200780007540.0 Country of ref document: CN |